Revolutionizing Psychiatric Care: Nanotechnology-Driven Nose-To-Brain Therapy

Anxiety and Depression are widespread mental health conditions that have a major influence on people's quality of life and overall health worldwide. The effectiveness of traditional pharmacological treatments is frequently limited by issues such systemic side effects, delayed therapeutic onset, and poor blood-brain barrier (BBB) penetration. One innovative way to overcome these constraints is through nanotechnology, especially with nose-to-brain drug delivery devices. Therapeutics can be delivered directly and quickly to the Central Nervous System (CNS) via the nasal route, which avoids the blood-brain barrier. Solid lipid nanoparticles (SLNs), polymeric nanoparticles, liposomes, and nanoemulsions are examples of nanocarriers that have shown great promise in improving medication targeting, bioavailability, and controlled release. This method lowers systemic exposure, increases patient compliance, and maximizes therapeutic results. This review examines the developments in nose-to-brain therapy for depression and anxiety that are powered by nanotechnology. Important nanocarrier systems, their modes of action, therapeutic uses, and the difficulties in clinical translation are highlighted. The revolutionary potential of these discoveries to alter psychiatric care and give those afflicted with these crippling conditions new hope is emphasized.